APOC3 anticorps

N° du produit ABIN289326

Détail du produit anti-APOC3 anticorps

Antigène: APOC3 (Apolipoprotein C-III (APOC3))

Reactivité: Humain

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp APOC3 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP)

Purification: Affinity chromatography purified

Immunogène: ApoC-III antibody was raised in goat using produced from apolipoprotein type C-III derived from human plasma as the immunogen.

Information d'application

Indications d'application: ELISA: 1:5,000-1:10,000, IHC: 1:50-1:200, IP: 1:100, WB: 1:5,000-1:10,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: Lot specific

Buffer: 0.125 M Na5 5 7, pH 8.0, with 0.075 NaCl, 0.005 EDTA, and 0.01 % NaN3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Détails sur APOC3

Antigène: APOC3 (Apolipoprotein C-III (APOC3))

Autre désignation: ApoC-III (APOC3 Produits)

Synonymes: anticorps APOC3, anticorps APOCIII, anticorps HALP2, anticorps Apoc, anticorps ApoC-III, anticorps apo-CIII, anticorps Apo-CIII, anticorps apolipoprotein C3, anticorps apolipoprotein C-III, anticorps APOC3, anticorps Apoc3

Sujet: Apolipoprotein C-III is a very low density lipoprotein (VLDL). APOC3 inhibits lipoprotein lipase and hepatic lipase, it is thought to inhibit hepatic uptake of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.

Pathways: Carbohydrate Homeostasis, Lipid Metabolism